Skip to main content

Medication

Amylin analogs

14-07-2023 | Type 2 diabetes | News

Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

26-11-2021 | Cagrilintide | News

Promising phase 2 results for long-acting amylin analog cagrilintide

The long-acting amylin analog cagrilintide promotes notable weight loss during 26 weeks of use, show phase 2 trial findings.

08-10-2021 | Artificial pancreas systems | News

Fully closed-loop insulin delivery not yet a match for precise carb counting

A dual-hormone fully closed-loop system did not demonstrate non-inferiority to a hybrid system in a randomized trial, despite producing a high time in range, report the researchers.

28-06-2021 | ADA 2021 | Conference coverage | News

Pramlintide, prandial insulin co-formulation gives benefits of both in one injection

A co-formulation of pramlintide and a prandial insulin offers improved postprandial glucose control and weight loss, without an increased number of injections, show the results of a small crossover trial.

Weight loss concept

04-05-2021 | Obesity | News

Cagrilintide, semaglutide combination warrants further investigation for weight loss

Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.

25-09-2020 | EASD 2020 | Conference coverage | News

Fully closed-loop insulin delivery edges closer with pramlintide–faster aspart system

A fully automated dual-hormone delivery system with pramlintide and faster-acting insulin aspart delivers overall glycemic control that is nearly as good as that achieved with a hybrid closed-loop system with the insulin only, report researchers at the virtual 56th EASD Annual Meeting.

Mixed diabetes medications

15-01-2018 | Type 1 diabetes | Hot topic review | Article

What do we know about adjunct non-insulin medications in type 1 diabetes?

medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.

23-08-2017 | Obesity | Review | Article

Weight management in patients with type 1 diabetes and obesity

Mottalib A et al. Curr Diab Rep 2017; 17: 92. doi: 10.1007/s11892-017-0918-8

16-03-2017 | Glycemic control | Review | Article

Metrics for glycemic control: From HbA1c to continuous glucose monitoring

Nat Rev Endocrinol 2017; 13: 425–436. doi: 10.1038/nrendo.2017.3